Skip Navigation


Annals of Oncology Advance Access originally published online on May 25, 2006
Annals of Oncology 2006 17(8):1269-1274; doi:10.1093/annonc/mdl100
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
17/8/1269    most recent
mdl100v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (1)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Vergnenegre, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Vergnenegre, A.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2006 European Society for Medical Oncology

Cost-minimization analysis of a phase III trial comparing concurrent versus sequential radiochemotherapy for locally advanced non-small-cell lung cancer (GFPC-GLOT 95–01)

A. Vergnenegre1,*, C. Combescure2, P. Fournel3, S. Bayle4, C. Gimenez5, P. J. Souquet6, H. Lena7, M. Perol8, J. Y. Delhoume9 GFPC (Groupe Français de Pneumo-Cancérologie)

1 CHU Limoges; 2 Université Montpellier 1, CHU Montpellier; 3 CHU Saint-Etienne; 4 CHU Brest; 5 CHU de Marseille; 6 CHU de Lyon Sud; 7 CHU de Rennes; 8 CHU de Lyon Croix Rousse; 9 CH de Périgueux, France

* Correspondence to: Prof. A. Vergnenegre, Service de Pathologie Respiratoire, Hôpital Universitaire du Cluzeau, 87042 Limoges cedex, France. Tel: +33-5-55-05-66-29; Fax: +33-5-55-05-68-15; E-mail: avergne{at}unilim.fr

Background: We conducted an economic analysis of a phase III clinical trial comparing sequential radiochemotherapy (RT-CT) with concurrent RT-CT in patients with locally advanced non-small-cell lung cancer.

Patients and methods: The trial was a randomized multicenter study comparing three cycles of chemotherapy (arm A) followed by radiotherapy against an RT-CT combination (two cycles of platinum etoposide) followed by two cycles of platinum-vinorelbine (arm B). The economic analysis adopted the payer's perspective and only included direct costs. Costs ({euro}, 1996–2003) were recorded until the cut-off date. A cost minimization analysis and a sensitivity analysis were carried out.

Results: Data from 173 patients were used in the economic study. Protocol costs tended to be higher in arm B, while relapse costs were significantly higher in arm A. The total number of hospital days was higher in arm B. The average total cost per patient was {euro}16 074 in arm A and {euro}15 245 in arm B (P = 0.15). The cost minimization analysis favored arm B. This advantage persisted in the sensitivity analysis.

Conclusions: Concurrent RT-CT was not the more costly strategy in this phase III trial, despite lengthier hospitalization for toxicity. Other studies of similar design are needed to confirm these results in future randomized trials.

Key words: cost minimization analysis, lung cancer, stage III NSCLC, radiochemotherapy, clinical trial


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.